Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome

Allison G. Dupont, Don A. Gabriel, Mauricio G Cohen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Acute coronary syndrome is the number one killer in the industrialized world and, as such, continues to be one of the most well-studied disease states in all of medicine. Advancements in antiplatelet therapies for use in patients undergoing percutaneous coronary intervention have improved outcomes dramatically. However, a proportion of patients on long-term antiplatelet therapy continue to have cardiovascular events. Resistance to antiplatelet drugs may explain some of these events and this topic has become one of major interest and rapid evolution. This review describes the pathogenesis of acute coronary syndromes, outlines the evidence behind the use of the available antiplatelet agents, and examines the current data surrounding antiplatelet resistance.

Original languageEnglish
Pages (from-to)6-13
Number of pages8
JournalThrombosis Research
Volume124
Issue number1
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Platelet Aggregation Inhibitors
Acute Coronary Syndrome
Percutaneous Coronary Intervention
Medicine
Therapeutics

Keywords

  • Acute coronary syndrome
  • Antiplatelet drugs
  • Antiplatelet resistance

ASJC Scopus subject areas

  • Hematology

Cite this

Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. / Dupont, Allison G.; Gabriel, Don A.; Cohen, Mauricio G.

In: Thrombosis Research, Vol. 124, No. 1, 01.05.2009, p. 6-13.

Research output: Contribution to journalArticle

@article{f9bca8358f8f4368bc80da623bea0ffa,
title = "Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome",
abstract = "Acute coronary syndrome is the number one killer in the industrialized world and, as such, continues to be one of the most well-studied disease states in all of medicine. Advancements in antiplatelet therapies for use in patients undergoing percutaneous coronary intervention have improved outcomes dramatically. However, a proportion of patients on long-term antiplatelet therapy continue to have cardiovascular events. Resistance to antiplatelet drugs may explain some of these events and this topic has become one of major interest and rapid evolution. This review describes the pathogenesis of acute coronary syndromes, outlines the evidence behind the use of the available antiplatelet agents, and examines the current data surrounding antiplatelet resistance.",
keywords = "Acute coronary syndrome, Antiplatelet drugs, Antiplatelet resistance",
author = "Dupont, {Allison G.} and Gabriel, {Don A.} and Cohen, {Mauricio G}",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.thromres.2009.01.014",
language = "English",
volume = "124",
pages = "6--13",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome

AU - Dupont, Allison G.

AU - Gabriel, Don A.

AU - Cohen, Mauricio G

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Acute coronary syndrome is the number one killer in the industrialized world and, as such, continues to be one of the most well-studied disease states in all of medicine. Advancements in antiplatelet therapies for use in patients undergoing percutaneous coronary intervention have improved outcomes dramatically. However, a proportion of patients on long-term antiplatelet therapy continue to have cardiovascular events. Resistance to antiplatelet drugs may explain some of these events and this topic has become one of major interest and rapid evolution. This review describes the pathogenesis of acute coronary syndromes, outlines the evidence behind the use of the available antiplatelet agents, and examines the current data surrounding antiplatelet resistance.

AB - Acute coronary syndrome is the number one killer in the industrialized world and, as such, continues to be one of the most well-studied disease states in all of medicine. Advancements in antiplatelet therapies for use in patients undergoing percutaneous coronary intervention have improved outcomes dramatically. However, a proportion of patients on long-term antiplatelet therapy continue to have cardiovascular events. Resistance to antiplatelet drugs may explain some of these events and this topic has become one of major interest and rapid evolution. This review describes the pathogenesis of acute coronary syndromes, outlines the evidence behind the use of the available antiplatelet agents, and examines the current data surrounding antiplatelet resistance.

KW - Acute coronary syndrome

KW - Antiplatelet drugs

KW - Antiplatelet resistance

UR - http://www.scopus.com/inward/record.url?scp=64749086877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749086877&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2009.01.014

DO - 10.1016/j.thromres.2009.01.014

M3 - Article

C2 - 19324398

AN - SCOPUS:64749086877

VL - 124

SP - 6

EP - 13

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 1

ER -